Abstract: Distinct subsets of dendritic cells (DCs) are present in blood, probably "en route" to different tissues. We have investigated the chemokines and adhesion molecules involved in the migration of myeloid (CD11c ؉ ) and plasmacytoid (CD123 ؉ ) human peripheral blood DCs across vascular endothelium. Among blood DCs, the CD11c ؉ subset vigorously migrated across endothelium in the absence of any chemotactic stimuli, whereas spontaneous migration of CD123 ؉ DCs was limited. In bare cell migration assays, myeloid DCs responded with great potency to several inflammatory and homeostatic chemokines, whereas plasmacytoid DCs responded poorly to all chemokines tested. In contrast, the presence of endothelium greatly favored transmigration of plasmacytoid DCs in response to CXCL12 (stromal cell-derived factor-1) and CCL5 (regulated on activation, normal T expressed and secreted). Myeloid DCs exhibited a very potent transendothelial migration in response to CXCL12, CCL5, and CCL2 (monocyte chemoattractant protein-1). Furthermore, we explored whether blood DCs acutely switch their pattern of migration to the lymph node-derived chemokine CCL21 (secondary lymphoid-tissue chemokine) in response to microbial stimuli [viral double-stranded (ds)RNA or bacterial CpG-DNA]. A synthetic dsRNA rapidly enhanced the response of CD11c ؉ DCs to CCL21, whereas a longer stimulation with CpG-DNA was needed to trigger CD123 ؉ DCs responsive to CCL21. Use of blocking monoclonal antibodies to adhesion molecules revealed that both DC subsets used platelet endothelial cell adhesion molecule-1 to move across activated endothelium. CD123
INTRODUCTION
Dendritic cells (DCs) are bone marrow-derived leukocytes specialized in antigen presentation to lymphocytes, which play an essential role in the initiation of primary immune responses [1] . A pool of DCs is distributed within peripheral tissues in an immature, functional state, characterized by a high rate of antigen capturing and processing to detect tissue invasion by pathogens. This subset of tissue resident-DCs is thought to be replenished by newly generated DC precursors, which migrate from the bone marrow presumably through the bloodstream. Upon recognition of pathogens or other "danger signals", resident-DCs initiate a program of functional maturation, which includes their mobilization from peripheral tissues to secondary lymphoid organs, where they present processed antigens to lymphocytes [2, 3] . This complex program of DC trafficking is tightly regulated by chemokine receptor expression and responsiveness during the DC life span. Most available data on this issue have been derived from in vitro-differentiated DCs [4] . In this regard, immature DCs derived from monocytes (mono-DCs) [5, 6] or CD34 ϩ precursors (CD34-DCs) [7] show comparable patterns of chemotactic response to CXCL12 [stromal cell-derived factor-1 (SDF-1)], CCL3 [macrophage-inflammatory protein-1␣ (MIP-1␣)], CCL4 (MIP-1␤), CCL5 [regulated on activation, normal T expressed and secreted (RANTES)], CCL7 [monocyte chemoattractant protein-3 (MCP-3)], CCL13 (MCP-4), and CCL22 (macrophage-derived chemokine), although CCL20 (MIP-3␣) only appears to induce migration of CD34-DCs. It is now well established that upon maturation, a striking change in the pattern of DC migration occurs. Hence, maturing DCs exhibit a rapid down-modulation of inflammatory chemokine receptor expression and function and the concomitant up-regulation of CCR7 [8 -10] . In this manner, the CCR7 ligands CCL19 (MIP-3␤) and CCL21 [secondary lymphoidtissue chemokine (SLC)], which are produced in lymphoid tissues, facilitate the emigration of maturing DCs from inflamed tissues and direct the homing of DCs to the T cell areas of lymphoid organs through lymphatic vessels [10, 11] . However, the in vitro differentiation of DCs might be unrelated to the in vivo process [12] , and the migratory properties of in vivodifferentiated DCs and DC precursors remain largely unknown.
Emigration of DCs from blood into tissue requires adhesion to and transmigration through vascular endothelium. Like other leukocytes, a number of adhesion molecules expressed on the DC or the endothelium [e.g., selectins, ␤ 1 (CD29) and ␤ 2 (CD18) integrins, vascular cell adhesion molecule-1 (VCAM-1), platelet-endothelial cell adhesion molecule-1 (PECAM-1/ CD31), and intercellular adhesion molecule-1 (ICAM-1)] may be involved in the transmigration of circulating DCs. In this regard, it has been shown that the transmigration of in vitroderived mono-DC is mediated by ␤ 2 integrins and PECAM-1 across resting endothelium and by ␣ 4 ␤ 1 (CD49e/CD29) across activated endothelium [13, 14] .
A heterogeneous population of DCs (or DC precursors) is found circulating in blood, which is currently identified by their high expression of human leukocyte antigen (HLA)-DR and lack of specific lineage markers found on other leukocytes [15, 16] . The physiological role of blood DCs is unclear, although it is thought that most of them are en route from the bone marrow to peripheral tissues or from nonlymphoid tissues to the regional lymph nodes and spleen. Based on the differential expression of CD11c, two main DC subsets have been originally identified in human blood [17] . The myeloid (CD11c ϩ ) DC population differentiates into mature DCs in response to inflammatory stimuli and expresses granulocyte macrophage-colony stimulating factor receptor and other myeloid cell markers, including CD13 and CD33 [18] . Conversely, the plasmacytoid (CD123 ϩ ) DC subset lacks myeloid cell markers, expresses high levels of the interleukin (IL)-3␣ receptor (CD123), and produces large amounts of type I interferon (IFN) upon exposure to viruses or bacteria [19, 20] .
Transendothelial migration (TEM) studies of blood DCs have been limited by the paucity of these cells, as they represent less than 1% of circulating peripheral blood mononuclear cells (PBMCs), as well as by their ability to rapidly initiate a program of maturation in culture or during cell purification procedures, which may modify their pattern of chemotactic response [10] . To overcome these problems, we have performed transmigration assays with unfractionated PBMCs and evaluated the number and type of blood DCs by flow cytometry before and after migration. In this manner, we have systematically examined the chemotactic response of blood DCs to a wide panel of chemokines through resting or activated endothelium and the adhesion molecules involved in their transendothelial passage. Our results indicate that the two main subsets of blood DCs display distinct patterns of TEM in response to chemokines and require differential endothelial adhesion support.
MATERIALS AND METHODS

Antibodies and chemokines
Monoclonal antibodies (mAb) against CD3, CD14, CD16, CD19, CD20, CD34, CD56 [each conjugated to fluorescein isothiocyanate (FITC)], CD11c, CD123, CD80, CD83 [each conjugated to phycoerythrin (PE)], HLA-DR [conjugated to peridinin chlorophyll protein (PerCP)], and nonbinding isotype-matched controls were purchased from Becton Dickinson (San Jose, CA). The anti-␤1 Lia1/2 [immunoglobulin G (IgG) 1 ] and K20 (IgG 2a ), anti-␣1 TS2/7, anti-␣2 Tea1/41, anti-␣3 VJ1/18, anti-␣4 HP1/2 (IgG 1 ), anti-␤2 Lia3/2 (IgG 1 ), antiCD11a TS1/11, anti-CD11b Bear-1, anti-CD11c HC1/1 integrins, anti-ICAM-1 HU5/3 (IgG 1 ), anti-ICAM-3 HP2/19, anti-PECAM-1 TP1/15 (IgG 2a ) , anti-VCAM-1 4B9 (IgG 1 ), and anti-HLA-A,B,C W6/32 (IgG 2a ) were a generous gift from Dr. Francisco Sánchez-Madrid (Hospital de la Princesa, Madrid, Spain). The anti-DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN; CD209) MR-1 mAb has been described previously [21] . The anti-␤3, anti-␣V, and anti-␣5 VC5 (IgG 1 ) integrins and anti-CCR5 (clone 2D7), anti-CXCR1 (clone 5A12), and anti-CXCR2 (clone 6C6) mAb were purchased from PharMingen (San Diego, CA). The anti-CCR1 (clone #53504.111), anti-CCR3 (clone #61828.111), anti-CCR6 (clone #53103.111), anti-CCR7 (clone #150503), anti-CXCR3 (clone #49801.111), and anti-CXCR4 (clone #44717.111) mAb were purchased from R&D Systems (Minneapolis, MN). The anti-CCR2 mAb (clone #04) was provided by Dr. Carlos Martínez-A (Centro Nacional de Biotecnología, Madrid, Spain). Human recombinant CCL2, CCL7, CCL8, CCL13, CCL19, SLC, CXCL8, CXCL9, and CXCL10 were purchased from PeproTech (London, UK). CCL3, CCL4, CCL5, CCL20, CCL22, and CXCL12 were obtained from R&D Systems. The activity of all the chemokines used was assayed in the appropriated responsive cell type (e.g., tumor-infiltrating lymphocytes were used to control CXCL9 and CXCL10 activity; granulocytes for CXCL8).
Cells and cell cultures
PBMCs were obtained from buffy coats by centrifugation over Ficoll-Hypaque (Lymphoprep TM , Nycomed Pharma AS, Oslo, Norway) and were resuspended in RPMI (Gibco-BRL Life Technologies, Paisley, Scotland), supplemented with 10% heat-inactivated fetal calf serum (FCS; Gibco-BRL Life Technologies). DCs were purified with a blood DC cell isolation kit (Miltenyi Biotec, Bergish Gladblach, Germany) to a purity Ն95%. All purification steps were performed at 4°C.
In some experiments, PBMCs were cultured at 37°C in the presence of polyinosinic:polycytidylic acid [poly(I:C); 50 g/ml; Sigma Chemical Co., St. Louis, MO]; oligodeoxynucleotides (ODN) in their phosphorothioate form AAC-30-CpG (5Ј-ACCGATAACGTTGCCGGTGACGGCACCACG) and nonstimulatory-GpC (5Ј-TGCTGCTTTTGTGCTTTTGTGCTT; 1 M; Amersham Pharmacia Biotech, Amersham, UK), as described [22] ; recombinant human CD40 ligand kit (CD40L 100 ng/ml; enhancer 1 g/ml; Alexis Biochemicals, Lausen, Switzerland); and IL-3 (10 ng/ml; PeproTech). In mAb-blocking experiments, PBMCs were preincubated with human IgG at 250 g/ml for 10 min at room temperature to block FcR binding and then with mAb at 20 g/ml for 15 min before TEM assays.
Human endothelial cells (ECs) from umbilical vein (HUVEC) were obtained and cultured as described previously [23] . Briefly, umbilical veins were cannulated, washed, and incubated with 0.1% collagenase P (Boehringer Mannheim GmbH, Mannheim, Germany) for 20 min at 37°C. Cells were seeded on tissue-culture flasks (Costar, Corning, NY) coated with 0.5% gelatine (Sigma Chemical Co.) and grown in 199 medium (Gibco-BRL Life Technologies) supplemented with 20% FCS, 50 IU/ml penicillin, 50 g/ml streptomycin (ICN Biomedicals, Costa Mesa, CA), 250 g/ml fungizone (Squibb Industria Farmacéutica, Barcelona, Spain), 50 g/ml EC growth supplement (prepared from bovine brain), and 100 g/ml heparin (Sigma Chemical Co.) and were used up to the third passage. For TEM assays, polycarbonate transwell membranes (COSTAR, Costar Europe, Badhoevedorp, The Netherlands) were coated with 20 g/ml fibronectin (Sigma Chemical Co.) at 37°C for 1 h before HUVEC seeding onto membranes (10 5 cell/transwell). HUVEC were grown as a monolayer for 24 h in a total volume of 200 l PANSERIN 401 serum-free medium (PAN Biotech GmbH, Aidenbach, Germany). To confirm the confluence of the HUVEC on the membrane and that ECs grew only on the upper side of the filter, sample monolayers were routinely stained with DiffQuik (American Scientific Products, McGraw Park, IL). To stimulate EC monolayers, tumor necrosis factor ␣ (TNF-␣; Alexis Biochemicals) at 50 ng/ml was added for 12 h. In mAb-blocking experiments, HUVEC monolayers grown on transwells were preincubated with mAb at 20 g/ml for 15 min before TEM assays.
TEM and chemotaxis assays
TEM and chemotaxis assays were performed using the transwell system (pore size 3 m) as previously reported [5] with some modifications. The polycarbonate transwell membranes were used uncoated for bare chemotaxis assays or coated with an EC monolayer for TEM assays. The endothelial monolayers were rinsed once with RPMI medium, and then, 1 ϫ 10 6 PBMCs were added in 100 l RPMI plus 10% FCS to the upper inserts. Inserts were transferred to wells (lower chambers) of 24-well plates containing 600 l fresh RPMI. In some experiments, various chemokines were also added at different concentrations to the lower chambers. Cells were allowed to transmigrate for 2 h at 37°C or the indicated time in chemotaxis assays. After migration, cells in the lower chamber were collected. Additionally, to recover eventually migrated cells bound to the lower side of the membrane, the lower surface of the insert was rinsed with 600 l ice-cold phosphate-buffered saline containing 10 mM EDTA. The cells that had migrated to the lower chamber were combined with those detached from the filter, and the total number of migrated cells was calculated by quantitative immunofluorescence flow cytometry (TruCOUNT analysis) in a FACScalibur flow cytometer (Becton Dickinson) as described previously [24] . TruCOUNT tubes, each one containing a known number of beads, were used to determine the absolute counts of DCs. A minimum of 500 Lin Ϫ , HLA-DR ϩ DC events, and/or 40,000 beads was acquired for each analysis. Each sample was analyzed in duplicate. The absolute number of DCs in each sample was calculated as the average of the duplicate tubes, each being determined by comparing the cellular events with bead events. The number of cells before and after migration was calculated for each phenotype, and the percentage of migration was calculated from these values. In addition, we checked that the culture of PBMCs in the presence of chemokines from 1 to 4 h did not modify the number or the proportion of blood DC subsets. We validated the results of DC TEM and chemotaxis obtained with total PBMCs using purified DC subsets, which in parallel experiments, showed a comparable pattern of response to chemokines.
Flow cytometry
Cells were preincubated with human IgG for 10 min at room temperature and then incubated with the appropriate mAb for 30 min at 4°C. To identify CD11c ϩ and CD123 ϩ peripheral blood DCs (PBDCs), triple staining with labeled mAb was performed with antilineage (CD3, CD14, CD16, CD19, CD20, CD34, CD56) FITC, anti-DR PerCP, and anti-CD11c PE or anti-CD123 PE. Blood DCs were defined within PBMCs as lineage-negative, HLA-DR ϩ cells that were CD11c ϩ or CD123 ϩ . Four-color cytometry was used to analyze the expression of adhesion molecules and chemokine receptors. PBMCs were incubated with corresponding mAb (1 g/ml), followed by washing and labeling with biotin-labeled goat anti-mouse Ig (Dako, Glostrup, Denmark), followed by allophycocyanin-labeled streptavidin (PharMingen). After a new washing, free goat anti-mouse Ig-binding sites were saturated by excess concentrations of mouse IgGs before exposing the cells to anti-CD3, -CD14, -CD16, -CD19, -CD20, -CD34, and -CD56 FITC, CD11c PE or anti-CD123 PE, and anti-DR PerCP-labeled mAb. Fluorescence flow cytometry acquisition and analysis were performed on a FACScalibur cytofluorometer (Becton Dickinson) using CellQuest software.
Statistic analysis
Data are presented as the mean Ϯ SD and compared by Student's t-test or one-way ANOVA. Multiple groups were compared by nonparametric ANOVA (Kruskal-Wallis test). If P Ͻ 0.05 were obtained, pairs of groups were further compared with nonparametric Mann-Whitney U-test.
RESULTS
Pattern of spontaneous migration and chemotactic response of blood DC subsets
A previous study on blood DCs showed an impaired capacity of plasmacytoid DCs to migrate to most chemokines [25] ; however, DC migration may be hampered by poor survival and maturation of isolated blood DCs. Therefore, we performed bare migration assays with unseparated PBMC preparations and monitored DC migration immediately ex vivo. The absolute number of DCs was assessed before and after migration through a 3-m porous membrane by TruCOUNT analysis. Blood DCs were defined within PBMCs as HLA-DR ϩ cells that were lineage (CD3, CD14, CD16, CD19, CD20, CD34, and CD56)-negative, and two main subsets were characterized in base of their differential expression of CD11c and CD123. We first analyzed the spontaneous migratory ability of blood DCs in the absence of any chemotactic stimuli. Before migration, the CD11c ϩ and CD123 ϩ subsets represented below 0.45 Ϯ 0.05% and 0.2 Ϯ 0.03% (meanϮSEM; nϭ10) of total PBMCs, respectively. (Fig. 1A shows a representative blood donor. ) Spontaneous migration revealed a major difference between DC subsets: After 1 h of migration, the CD11c ϩ subset was highly enriched and represented approximately 2.06 Ϯ 0.11% (nϭ10) of migrated PBMCs, whereas the CD123 ϩ subset was approximately 0.19 Ϯ 0.06% (nϭ10). Figure 1C shows a representative time course experiment in which almost 20% of the starting population of CD11c ϩ cells spontaneously migrated to the lower chamber after 2 h, in clear contrast with the lower migration of CD123 ϩ cells. At this time point, the CD11c ϩ subset was clearly identified within migrated PBMCs, whereas the CD123 ϩ subset was nearly absent (Fig. 1B) . As CXCL12 (SDF-1) has been reported to attract both subsets of blood DCs [7] , the kinetic of the response to this chemokine was also analyzed. CD11c ϩ cells showed a substantial increment over basal migration in response to CXCL12, which reached its maximum after 2 h of migration; however, a significantly lower percentage of CD123 ϩ cells responded to CXCL12 (Fig. 1D) . Furthermore, similar responses to CXCL12 were obtained using total PBMCs or purified blood DCs (Fig. 1E ), indicating that both migration assays yield comparable results.
We also performed bare migration assays using total PBMCs to a wide panel of chemokines. As shown in Figure 2 , CD11c ϩ DCs migrated with great potency to CCL2, CCL8, CCL7, and CXCL12. The absolute number of CD11c ϩ DCs mobilized in response to these chemokines was very high, with CXCL12 attracting more than 80% of the initial population after 1 h of migration. In addition, the CD11c ϩ subset moderately responded to CCL13, CCL5, and CCL3 and migrated weakly or did not migrate in response to CCL4, CCL19, CCL20, CCL21, CCL22, CXCL8, CXCL9, and CXCL10 ( Fig. 2A) . In contrast, the CD123 ϩ subset poorly responded to most of the chemokines tested, in spite of a modest response to CXCL12 (Fig.  2B ). Dose-response curves to chemokines were also performed, and the chemotactic responses of both DC subsets were analyzed. CD11c
ϩ DCs migrated to CCL2, CCL3, CCL5, CCL7, CCL8, and CCL13 in a dose-dependent manner, whereas CD123
ϩ DCs weakly responded to higher doses of these chemokines (Fig. 2 , C-E; data not shown). Doses as high as 500 ng/ml were assayed for CCL19, CCL20, CCL21, CCL22, CXCL8, CXCL9, CXCL10, and CXCL11 without a significant increase in blood DC chemotaxis (data not shown). The doseresponse curves of both DC subsets toward CXCL12 were bell-shaped, reaching a maximum at 50 ng/ml for CD11c ϩ cells and at 100 ng/ml for CD123 ϩ cells, respectively (Fig. 2F ). These results indicate that in bare migration assays, CD11c ϩ DCs are highly motile cells, which respond with great potency to inflammatory and homeostatic chemokines, whereas CD123
ϩ DCs only respond with very low potency to CXCL12. Therefore, the chemotactic responses of blood DCs obtained with unfractionated PBMCs were consistent with previous studies performed with purified DCs [25] , suggesting that additional factors to DC isolation procedures may account for the impaired ability of plasmacytoid DCs to migrate.
Migratory response to chemokines of blood DCs across endothelial monolayers
To test whether adhesive interactions with endothelial ligands may affect DC migration, we performed TEM assays. To this end, transwell membranes were coated with endothelial monolayers, which were resting or TNF-␣-activated (Fig. 3) . After 2 h of transmigration, a significant level of spontaneous migration of CD11c ϩ DCs was observed through resting and TNF-␣-activated endothelium (percentage of migrated cells: 20.6Ϯ6.3%, nϭ5 donors, and 29Ϯ10.8%, nϭ9, respectively; Fig. 3A shows a representative donor), whereas the baseline migration of the CD123 ϩ subset was much lower (resting endothelium 2.3Ϯ1.6% and TNF-␣-activated endothelium 2.9Ϯ2.6%, nϭ5 donors; Fig. 3A ). In the case of CD11c ϩ DCs, migration was higher in response to CXCL12 (90.3Ϯ7.6%, nϭ7) and CCL5 (78.5Ϯ13.5%, nϭ8; Fig. 3A) . Similarly, CD123
ϩ DCs strongly migrated across endothelium in response to CXCL12 (52Ϯ16.2%, nϭ7) and exhibited a significant migratory response to CCL5 (30Ϯ8.7%, nϭ8; Fig. 3A) . Therefore, the presence of an endothelial monolayer greatly favored the migration of CD123 ϩ DCs. For comparative purposes, the transmigration responses of purified blood DCs to the more active chemokines CCL2, CCL5, and CXCL12 were also analyzed (Fig. 3B) . As expected, both DC subsets strongly responded to CXCL12. CD123
ϩ DCs responded moderately to 
CCL5 and less to CCL2, whereas CD11c
ϩ DCs equally responded to CCL2 and CCL5. Therefore, CD123 ϩ and CD11c ϩ DCs significantly migrate across endothelium toward CXCL12 and CCL5, but they differ in their ability to spontaneously transmigrate and in their response to the inflammatory chemokine CCL2. We also analyzed the chemokine receptor expression by blood DC subsets using multicolor flow cytometry, and results are summarized in Table 1 . The important chemotactic response to CXCL12 by CD123 ϩ and CD11c ϩ DCs correlated well with the high expression of its cognate receptor CXCR4 by both subsets. Similarly, the response to CCL5 by both DC subsets correlated with an important expression of CCR5. CD11c ϩ DCs expressed high levels of CCR2 and migrated well in response to CCL2. By contrast, CD123
ϩ DCs highly expressed CXCR3 and CCR7 but transmigrated poorly in response to their ligands CXCL9, CXCL10, and CXCL11 or CCL19 and CCL21, respectively ( Fig. 3; data not shown) .
Maturation of blood DCs by overnight in vitro culture has been reported to induce up-regulation of CCR7 function and enhance CCL19/CCL21-dependent migration [10] . We explored whether the migratory properties of blood DCs can be rapidly modified in response to pathogen-derived products, which may be found in peripheral blood during infectious processes. To test this hypothesis, PBMCs were challenged for 1-24 h with different nucleic acids: viral double-stranded (ds)RNA or bacterial DNA containing unmethylated CpG, reported to stimulate, respectively, CD11c ϩ and CD123 ϩ DCs [22] . Before stimulation, the specific migration in response to CCL21 was lower for CD123 ϩ DCs than for CD11c ϩ DCs (8.6Ϯ3.5% and 28.1Ϯ7.3%, respectively, nϭ6). After 1 h of treatment with a synthetic dsRNA, poly(I:C), CD11c
ϩ DCs rapidly enhanced their response to CCL21 (Fig. 4A) , which correlated with a mild increase in the expression of CCR7 (data not shown). In contrast, a longer stimulation with bacterial CpG-DNA (24 h) was needed to trigger a mild response of CD123 ϩ DCs to CCL21 (Fig. 4B) . A better response to CCL21 was achieved after 24 h activation with IL-3/CD40L (Fig. 4B) , which has been documented previously [25] . Altogether, these data suggest that following short stimulation with microbial stimuli, CD11c ϩ DCs are able to acutely respond to the lymph node-derived chemokine CCL21, whereas CD123 ϩ DCs do not respond so rapidly.
Adhesion molecules involved in blood DC TEM
The relative levels of expression of ␤ 1 and ␤ 2 integrins, several members of the Ig superfamily such as ICAM-1, ICAM-3, VCAM-1, and PECAM-1, and the DC-specific adhesion receptor DC-SIGN were studied on blood DCs by flow cytometry. As shown in Table 1 , blood DCs expressed high levels of ␣ 4 (CD49d) and ␣ L (CD11a) integrins, which may mediate adhesion to endothelium. It is interesting that no expression of DC-SIGN was detected in blood DC subsets.
Next, to address the specific contribution of each adhesion molecule to the process of DC transmigration, TEM assays were performed in the presence of blocking mAb to ICAM-1, PECAM-1, and ␤ 1 and ␤ 2 integrins. CXCL12 was used as a migration inducer in these experiments, as it promotes maximal transmigration in both DC subsets. TEM, across resting endothelium of both DC subsets, was inhibited by 60 -70% with anti-␤ 2 integrin mAb; however, no inhibition was observed with anti-ICAM-1 mAb (Fig. 5A) . Because in the same experiments, the anti-ICAM-1 mAb effectively inhibited the migration of monocytes and lymphocytes (Fig. 5A) , it is possible that other ␤ 2 -integrin endothelial ligands such as ICAM-2 could play a role in the transmigration ability of blood DCs through resting endothelium. Anti-␤ 1 -integrin mAb also inhibited migration of DCs across resting endothelium. This inhibition may correspond to blocking of leukocyte interactions with underlying extracellular matrix (ECM) secreted by HUVEC, as the endothelial preparations used in these studies did not express VCAM-1, as assessed by immunofluorescence flow cytometry, and anti-VCAM-1 mAb did not inhibit transmigration across resting endothelium (data not shown). In addition, to assess the role of endothelial cytokine-inducible molecules, TEM experiments were performed across TNF-␣-stimulated endothelium (Fig. 5B) . Under these conditions, transmigration of CD11c ϩ DC was partially inhibited by anti-PECAM-1 mAb and was weakly or not affected by blocking anti-ICAM-1, anti-␤ 1 , or anti-␤2 mAb (Fig. 5B) . On the contrary, CD123
ϩ DC transmigration could be blocked by anti-␤ 2 , anti-␤ 1 , anti-ICAM-1, or anti-PECAM-1 mAb (Fig. 5B) . We also used anti-␤ 1 and -␤2 mAb in combination, which was more effective than blocking each integrin alone (Fig. 5C ). However, a large portion of CXCL12-induced CD11c ϩ DC migration across activated endothelium was independent of ␤ 1 and ␤2 integrins. Taken together, these results may indicate that PECAM-1 may support transmigration of both DC subsets through stimulated endothelium. In addition, functional ␤ 1 and ␤ 2 integrins support the adhesion/transmigration of CD123 ϩ DCs across resting and stimulated endothelium and of CD11c ϩ DCs across resting endothelium. By contrast, under endothelial activation, CD11c
ϩ DCs appear to be highly motile cells whose transmigration was weakly inhibited by antibodies against ␤1 and ␤2 integrins, compared with other leukocytes.
DISCUSSION
In this study, we show that myeloid and plasmacytoid blood DCs exhibit fundamental differences in their migratory ability: Myeloid DCs are highly migratory cells that move even in the absence of any chemotactic gradient and without requiring endothelial support, whereas plasmacytoid DCs show very low spontaneous migration and are highly dependent on endothelial support to transmigrate. The pattern of response to chemokines of both DC subsets is also different: Myeloid DCs strongly respond to inflammatory and homeostatic chemokines, whereas plasmacytoid DCs selectively transmigrate in response to CXCL12 and CCL5. Our data indicate the existence of diverse migratory properties among distinct subsets of circulating DCs, which may reflect their in vivo pattern of tissue traffic.
We performed migration assays with whole peripheral blood leukocytes, taking advantage of the combination of migration assays with cell counting of minor leukocyte populations by quantitative flow cytometry. Our results were highly reproducible, despite blood DCs representing a minor subpopulation of leukocytes, and were consistently observed among different blood donors. This methodology allowed us to study the pattern of migration of unmanipulated blood DCs in response to a number of chemokines and their ability to interact with endothelium. We show that the response to chemokines of unmanipulated blood DCs is similar to purified blood DCs and thus is compatible with bare migration assays performed with enriched DCs [25] . However, bare migration assays are limited and have little impact, as cell migration requires the interaction of adhesion receptors with ligands provided by ECM or intercellular adhesion molecules expressed by supporting cells. To migrate, some leukocytes such as lymphocytes are highly dependent on the interaction with intercellular adhesion molecules (such as ICAM-1 and -2, expressed by resting endothelium, or VCAM-1, expressed by activated endothelium) [26] . Therefore, we performed migration assays in the presence of EC monolayers, which provide adhesion molecules as well as synthesize ECM proteins, and together, support cell adhesion and transmigration. Previous work, performed in the absence of endothelial support, reported that plasmacytoid cells are drastically impaired to migrate to most chemokines [25] . It is interesting that plasmacytoid DCs are highly dependent on endothelial support to transmigrate. When well positioned to migrate across endothelium, this subset responds importantly to CXCL12 and CCL5, chemokines that may drive the accumulation of plasmacytoid DCs under pathological settings.
At least some blood DCs are hypothesized to be en route from bone marrow to tissues, where they immigrate to become tissue resident-DCs [1] . Our data indicate that CXCL12 may play a major role in the steady-state recruitment of blood DCs directly from blood to tissues. CXCL12 mRNA has been reported to be expressed in many different tissues [27] , although it is preferentially expressed in lymph nodes, lung, liver, and bone marrow and less in small intestine, kidney, skin, brain, and skeletal muscle [28] . In addition, CXCL12 may also play a role in the recruitment of DCs to inflamed tissues, as CXCL12 is strongly up-regulated in the joint synovium of rheumatoid arthritis and may also contribute to skin inflammatory responses [29 -31] . The bell-shaped, dose-response curves to CXCL12 suggest that myeloid DCs respond maximally to lower doses of CXCL12 than plasmacytoid DCs. Thus, it is possible that myeloid DCs migrate preferentially to tissues expressing low levels of CXCL12, whereas plasmacytoid DCs may migrate to tissues that express higher doses of CXCL12, such as lymph nodes. This is compatible with the reported presence of plasmacytoid DCs, but not myeloid DCs, in tumors expressing high levels of CXCL12 [32] . Previous work, based on the expression of CXCR3 and L-selectin (CD62L) by plas- macytoid DCs [19] , had postulated that these cells migrated into the lymph node through high endothelial venules (HEV) in response to CXCL9 or CXCL10. In accordance, it has been recently described that plasmacytoid DCs are reduced in frequency in L-selectin-deficient mice [33] . However, our data indicate that plasmacytoid DCs transmigrate specifically to CXCL12 and CCL5, with rather weak chemotaxis toward CXCL9, CXCL10, and CXCL11, even through activated endothelium, which support CD62L-mediated leukocyte adhesion [34] . In this regard, it has been reported that CXCL12 is displayed broadly on HEV, and CXCL12 ectopic expression induces small infiltrates enriched in DCs [35, 36] . In addition to blood and organized lymphoid tissue, plasmacytoid DCs have also been identified in nasal mucosa during allergic reactions [37] and in cutaneous lesions of lupus erithematosus [38] . We have also found that plasmacytoid DCs migrated in response to CCL5, whose expression has been associated with a wide range of inflammatory disorders and pathologic conditions [39] . Emigration of plasmacytoid DCs to tissues may be of pathogenic relevance in those inflammatory diseases associated with up-regulated CCL5 and/or CXCL12 expression. Conversely, inducible chemokines, such as CCL5 and CCL2, may play an important role in the recruitment of myeloid DCs into inflamed tissues. In this regard, it has been reported that the treatment of rats with the selective antagonist of CCR1 and CCR5, Met-RANTES, importantly reduces the recruitment of DC precursors into airway epithelium [40] . The strong, migratory response of myeloid DCs to CCL2 and CCL5 might allow their rapid accumulation within inflamed tissues and explain why DCs are the earliest detectable leukocytes arriving at mucosal surfaces upon pathogen invasion [41, 42] . It is interesting that the responsiveness of myeloid DCs to CCL2 is a major difference with in vitro-derived DCs, as the latter do not migrate in response to CCL2 (data not shown; refs. [4, 5] ).
Besides a role as precursors of tissue resident-DCs, at least some blood DCs may act as environmental sentinels circulating in blood to detect pathogen invasion. Therefore, blood DCs may capture pathogenic antigens that can access the bloodstream and afterwards, mature and emigrate directly from blood to lymph nodes. In this regard, we have shown the ability of myeloid DCs to respond to the lymph node chemokine CCL21 upon acute viral dsRNA challenge, which points out their ability to detect the presence of pathogens in the bloodstream. The positive effect of poly(I:C) in the response of myeloid DCs to CCR7 ligands is in agreement with the very high level of expression of its receptor Toll-like receptor (TLR)3 by CD11c ϩ DCs [43] . Thus, poly(I:C) selectively stimulated CD11c ϩ DCs to produce IFN-␣ and IL-12p75, whereas plasmacytoid DCs do not express TLR3 and do not respond to poly(I:C). Plasmacytoid DCs express high levels of TLR9 and CCR7; however, they were not responsive to CCL21, neither resting nor after short ϩ and CD123 ϩ DC subsets by pathogen-derived products. Before migration, PBMCs were incubated for the indicated times in the absence or in the presence of the specified stimuli. Following stimulation, PBMCs were allowed to migrate for 2 h across TNF-␣-activated endothelium in the absence of chemokine or in response to 100 ng/ml CCL21. Results are expressed as in Figure 1 and represent the percentage of migrated input cells. Data are means Ϯ SD of duplicate samples of a representative experiment out of three.
activation with the TLR9 ligand ODN containing unmethylated CpG motifs. CpG-DNA and other stimuli reported to induce maturation of this subset, such as CD40L plus IL-3, partially rendered plasmacytoid DC responsive to CCL21 after prolonged stimulation (24 h).
In addition to chemokines that guide the emigration of responsive subsets of leukocytes to target tissues, extravasation is supported by a multistep cascade of adhesive interactions with endothelium [26, 44] . Both subsets of blood DCs uniformly express molecules involved in the initial adhesion under flow, such as P-selectin glycoprotein ligand-l and its isoform cutaneous lymphocyte-associated antigen [45] . We show that blood DCs also uniformly express ␣ 4 (CD49d) integrins, which like selectins, may support rolling [46] . By contrast, no blood DC subset expresses the DC-specific adhesion receptor DC-SIGN, a C-type lectin that has been reported to mediate the transmigration of mono-DCs [47] . To investigate adhesion molecules involved in TEM of both DC subsets, we induced transmigration with CXCL12 to achieve a maximal DC transmigration. An interesting observation is the fact that under CXCL12-induced TEM, blockade of ␤ 1 integrins partly inhibited migration of most leukocytes, across resting and activated endothelium. These results agree with a previous work reporting that CXCL12 stimulates lymphocytes to use ␤ 1 integrins in addition to ␤ 2 integrins across activated endothelium [48] . Chemokine-induced ␤ 1 -integrin activation [26] can mediate adhesion to ECM proteins produced by HUVEC, and thus, in addition to very late antigen (VLA)-4, other ␤ 1 integrins such as VLA-5 may mediate chemokine-induced TEM [49] . Similar to previous monocyte TEM studies [50] , we did not observe differences in the number of DCs that migrated across resting or TNF-␣-stimulated endothelium. A previous study by Brown et al. [51] found that endothelial activation increased the attachment of blood DCs, and it was dependent on ␤ 1 and ␤ 2 integrins. It is possible that enhanced DC adhesion to activated endothelium may counteract the up-regulation of endothelial adhesion molecules. However, we did observe some differences in the role of adhesion receptors between resting and stimulated endothelium. The contribution of PECAM-1 to DC transmigration appears to be more important across activated endothelium. Transmigration of plasmacytoid DCs is supported by ␤ 1 and ␤ 2 integrins across resting and activated endothelium, but migration of myeloid DCs is only dependent on ␤ 1 and ␤ 2 integrins across resting endothelium. It is interesting that transmigration across activated endothelium of the highly migratory myeloid DCs was not inhibited by anti-␤ 1 -and -␤ 2 -integrin mAb and only partially by a combination of anti-␤ 1 -and -␤ 2 -integrin mAb, suggesting that an additional, unrecognized pathway is also involved in TEM of myeloid DCs to CXCL12.
In conclusion, this study points out the existence of important differences in the migratory ability between distinct subsets of blood DCs. Adding on the understanding of the multiple factors governing the traffic of DCs may offer us the opportunity to design novel, therapeutic strategies based on targeting the appropriate DC subset to selective tissues such as tumors.
